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Heparin acts as a structural component of
b-endorphin amyloid fibrils rather than a simple
aggregation promoter†
N. Nespovitaya, P. Mahou, R. F. Laine, G. S. Kaminski Schierle and C. F. Kaminski*
The aggregation promoter heparin is commonly used to study the
aggregation kinetics and biophysical properties of protein amyloids.
However, the underlying mechanism for amyloid promotion by
heparin remains poorly understood. In the case of the neuropeptide
b-endorphin that can reversibly adopt a functional amyloid form in
nature, aggregation in the presence of heparin leads to a loss of
function. Applying correlative optical super-resolution microscopy
methods, we show that heparin incorporates into emerging b-endorphin
fibrils forming an integral component and is essential for amyloid
templating. This will have direct implications on b-endorphin’s
normal physiological function and raises concerns on the biological
relevance of heparin-promoted amyloid models.
The endogenous opiate b-endorphin is an essential neuropeptide
involved in the stress response of higher organisms.1 In the
secretory pathway, it is temporarily stored in dense-core vesicles
in the amyloid form, which disaggregates upon vesicle secretion
into the blood.2,3 The reversibility of aggregation of b-endorphin
and some other neuropeptides renders them fundamentally
diﬀerent from most functional amyloids, and probably all
disease-related amyloids, which aggregate irreversibly.2–5
Previous work on b-endorphin aggregation investigated
structure–activity relationships of amyloids induced by high-
and low-molecular-weight aggregation promoters, including
heparin and salts of polyprotic acids.3
Heparin is one of the most commonly used promoters of
aggregation. However, its mechanism of action is a subject of
considerable debate.6 Studies with transmission electron micro-
scopy (TEM), fluorescence and NMR spectroscopy revealed
morphological and structural diﬀerences between b-endorphin
aggregates induced with heparin, and those that were not (see
Fig. 1). Moreover, heparin-promoted amyloids demonstrated
an increased stability in dissociation assays.3 These dramatic
changes in fibril structure and function raise fundamental
questions on the role of heparin in protein aggregation.
Our working hypothesis in the present study is that heparin
is not simply a molecular crowding agent, as suggested in
recent models,7,8 but instead that it co-aggregates with the
peptide into a composite amyloid, at least in the case of
b-endorphin. This, in turn, leads to a change of the biophysical,
dynamic structural properties of the b-endorphin amyloid and
its morphology. We thus predicted for heparin to be associated with
the peptide along the whole fibril axis and tested this hypothesis
with two-colour optical super-resolution microscopy (SRM).9
Fig. 1 Comparative visualisation of b-endorphin amyloid fibrils obtained
in the presence (a and c) and absence of heparin (b and d). TEM (a and b)
and AFM (c and d) images show heparin-promoted fibrils as long individual
filaments, while b-endorphin amyloids formed in heparin-free aggregation
buﬀer are short and form bundles. In all case, fibrils were obtained at
60 mM peptide concentration (a–d) and 20 mM heparin (a and c). In all
cases, aggregation buffer was composed of 50 mM sodium phosphate and
2 mM sodium citrate at pH 6.0. Scale bars are 1 mm.
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In combination with diﬀerential labelling, SRM permitted an
unambiguous identification of the labelled compounds and
their relative arrangement at a nanometric scale.9–11 Importantly,
alternative high-resolution methods of structural biology, such as
NMR spectroscopy and X-ray crystallography, cannot address the
question of peptide-heparin colocalisation, due to the structural
heterogeneity of natural heparin.12 Alternative high-resolution
microscopy method such as TEM used in combination with
immunogold labelling overcomes that latter disadvantage,
however, has comparatively low resolution because of the large
sizes of gold particles and linker lengths.13 The technique is
also hampered by the sparse labelling density usually achieved.
Moreover, it does not permit the reliable differentiation of de
novo fibril growth from the original seed species.
Using two-colour direct stochastic optical reconstruction
microscopy (dSTORM)14 we made two key findings: (1) heparin
co-aggregates with b-endorphin and becomes a structural element
of the amyloid, and (2) heparin-promoted fibrils are not capable of
templating the amyloid growth in the absence of heparin.
In order to test our hypothesis of colocalisation of b-endorphin
and heparin within the fibrils, we obtained b-endorphin amyloids
by co-incubation of the peptide labelled with AlexaFluor 568 dye
(AF568) and heparin conjugated with AlexaFluor 647 (AF647) and
imaged them with two-colour dSTORM. The fibrillar nature of the
obtained sample was confirmed by atomic force microscopy (AFM,
Fig. 2a). Further, 350 fibrils identified in 35 random fields of view
showed colocalisation of fluorescent signals in both the peptide
and heparin imaging channels (exemplified in Fig. 2b–d).
A pixel-based analysis of b-endorphin and heparin colocalisation
within the amyloid fibrils further supports this visual observation
(ESI,† Fig. S1). To ensure that fluorescence images were good
representations of b-endorphin fibrils, we used stimulated
emission depletion (STED)15 microscopy correlated with AFM.
b-Endorphin fibrils labelled with AF647 attached to either the
peptide (Fig. 2e and f) or to heparin (Fig. 2g and h) were imaged
with STED and then with AFM. All structures observed by AFM
had fibrillar shapes and exhibited the fluorescence signal every-
where along the fibril axis, confirming that all optical images
were adequate representations of b-endorphin fibrils and that
heparin was evenly distributed along the fibrils. The data
obtained here by two independent SRM techniques provide
unequivocal evidence of the tight association of heparin with
the b-endorphin amyloid fibrils. Next, we tested whether heparin
becomes an integral component of b-endorphin fibrils or associates
unspecifically with the amyloid. We performed an elongation assay
where fibrillar seeds of b-endorphin amyloids were incubated with
the monomeric peptide under various conditions (see Fig. 3
cartoons). Two-colour dSTORM demonstrated that heparin-
promoted b-endorphin amyloids grow by incorporation of both
the peptide and heparin into the fibril termini (Fig. 3b–d). At
the same time, heparin-promoted fibril seeds incubated with
monomeric b-endorphin in the heparin-free environment did
not elongate axially and appeared as short two-colour fibrils
(Fig. 3e, f and ESI,† Fig. S2), which suggests lateral adhesion of
the added monomer on the seed surface. This notion is
supported by a comparative AFM analysis of fibril height before
Fig. 2 b-Endorphin and heparin are associated within amyloid fibrils. The fibrillar nature of heparin-promoted b-endorphin aggregates labelled with two
fluorophores was confirmed by AFM (a). The fibrils were obtained at 60 mM total peptide concentration including 10% (mol) of the AF568-labelled peptide
(b, green) and 20 mM heparin labelled with AF647 (c, magenta). Colocalisation is displayed in (d, white), where super-resolved images from (b, green) and
(c, magenta) are merged. Further, b-endorphin fibrils containing AF647 fluorophore attached either to the peptide (e and f) or to heparin (g and h) were
examined by correlated STED/AFMmicroscopy. A field of viewwas first acquired via STED (e and g) and subsequently probed by AFM (f and h). Optical images
are seemed to fully reflect the fibrillar morphology of b-endorphin amyloids with either labelling scheme. Scale bars are 1 mm in a–d and 2 mm in e–h.
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and after the elongation assay, which indeed revealed that the
seeds thicken upon the addition of the monomeric peptide
(ESI,† Fig. S3). Notably, b-endorphin amyloids elongated in the
presence of heparin retained twisted fibrillar morphology similar
to parental heparin-promoted seeds (ESI,† Fig. S4).
In summary, our experiments demonstrate the coaggregation
of heparin and b-endorphin into composite amyloid fibrils. The
data obtained via two-colour dSTORM explain previously reported
striking diﬀerences between the properties of heparin-promoted
and heparin-free b-endorphin amyloids.3 The association of
heparin with the peptide leads to a fundamentally diﬀerent fibril
structure that renders the aggregation process irreversible, and,
hence, leads to a loss of function of b-endorphin amyloids,3 which
in nature is required to reversibly interchange between aggregated
and monomeric states. Our findings have significant implications
for the interpretation of structure–activity relationships and raise
concerns on the biological relevance of heparin-promoted amyloid
models. The latter is especially relevant for b-endorphin and other
functional hormone amyloids since the concentration of heparin
in the secretory pathway is insignificant.12 Given the widespread
adoption of heparin as a universal aggregation promoter,2,16–20
the presented findings are quite generally relevant to the field of
amyloid research.
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